4//SEC Filing
Mathew Aby J. 4
Accession 0001628280-25-028700
CIK 0000834365other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:04 PM ET
Size
6.7 KB
Accession
0001628280-25-028700
Insider Transaction Report
Form 4
Mathew Aby J.
EVP & Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-05-28$22.46/sh−521$11,702→ 308,486 total - Award
Common Stock
2025-05-29+45,269→ 353,755 total
Footnotes (2)
- [F1]The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
- [F2]The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the fourth anniversary of the measurement date of 05-29-2025.
Documents
Issuer
BIOLIFE SOLUTIONS INC
CIK 0000834365
Entity typeother
Related Parties
1- filerCIK 0001556355
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:04 PM ET
- Size
- 6.7 KB